Search by Drug Name or NDC
NDC 00069-1195-30 Talzenna 1 mg/1 Details
Talzenna 1 mg/1
Talzenna is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is TALAZOPARIB TOSYLATE.
MedlinePlus Drug Summary
Talazoparib is used to treat certain types of breast cancer that has spread within the breast or to other areas of the body. Talazoparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by stopping or slowing the growth of cancer cells.
Related Packages: 00069-1195-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Talazoparib
Product Information
| NDC | 00069-1195 |
|---|---|
| Product ID | 0069-1195_207b4971-3031-45d7-b6a4-dfe66b37650c |
| Associated GPIs | 21535580400120 |
| GCN Sequence Number | 079148 |
| GCN Sequence Number Description | talazoparib tosylate CAPSULE 1 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 45596 |
| HICL Sequence Number | 045368 |
| HICL Sequence Number Description | TALAZOPARIB TOSYLATE |
| Brand/Generic | Brand |
| Proprietary Name | Talzenna |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | talazoparib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 1 |
| Active Ingredient Units | mg/1 |
| Substance Name | TALAZOPARIB TOSYLATE |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA211651 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00069-1195-30 (00069119530)
| NDC Package Code | 0069-1195-30 |
|---|---|
| Billing NDC | 00069119530 |
| Package | 1 BOTTLE in 1 CARTON (0069-1195-30) / 30 CAPSULE in 1 BOTTLE |
| Marketing Start Date | 2018-10-26 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |